Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.72 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.71 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.66 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.66 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2941152 | 0.96 | S1PR1 (0.77) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2945539 | 0.92 | S1PR1 (0.72) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1384038 | 0.89 | S1PR1 (0.74) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL4690874 | 0.88 | S1PR1 (0.61) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2943950 | 0.88 | S1PR1 (0.77) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1382315 | 0.88 | S1PR1 (0.93) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2947262 | 0.87 | S1PR1 (0.64) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2942256 | 0.87 | S1PR1 (0.64) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2942159 | 0.87 | CACNA1G (0.65) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2942163 | 0.87 | CACNA1G (0.65) | S1PR1S1PR3CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | claimed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | claimed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-7750040-B2 | G protein-coupled receptor S1P1/EDG1 agonists; low dosage, long lasting immunosuppressive effect; such as 1,1,2-trimethyl-1,1a,5,5a-tetrahydro-3-thia-cyclopropa[a]pentalene-4-carboxylic acid 2,4-dimethoxy-benzylamide | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20080064740-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-03-13 | — | — | US | disclosed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064740-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | S1PR1 1258/4885S1PR3 1088/4885CACNA1G 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.